{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.58","upperLimit":"1.91","value":"1.7"},{"groupId":"OG001","lowerLimit":"0.89","upperLimit":"2.76","value":"1.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"PFS as per RECIST 1.1 was defined as the time from the date of first dose of study treatment until the date of objective disease progression or death by any cause in the absence of progression, regardless of whether the participant withdrew from study therapy or received another anti-cancer therapy prior to progression (date of PFS event or censoring - date of first dose + 1). Confidence interval was calculated using Kaplan-Meier technique.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants with osteosarcoma and Ewing sarcoma, rhabdomyosarcoma, non rhabdomyosarcoma soft tissue sarcoma, and other sarcomas were included in this arm. Participants were administered durvalumab 30 mg/kg IV in combination with tremelimumab 1 mg/kg IV in Cycles 1-4 every 28 days. From Cycle 5 onwards participants were administered durvalumab 30 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever occurred first.","id":"OG000","title":"SARCOMA: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg"},{"description":"Participants with solid tumor other (STO) were included in this arm. Participants were administered durvalumab 30 mg/kg IV in combination with tremelimumab 1 mg/kg IV in Cycles 1-4 every 28 days. From Cycle 5 onwards participants were administered durvalumab 30 mg/kg every 28 days until clinical or confirmed disease progression or until any of other discontinuation criterion was met, whichever came occurred first.","id":"OG001","title":"STO: Durvalumab 30 mg/kg + Tremelimumab 1mg/kg"}],"paramType":"MEDIAN","populationDescription":"The FAS included all participants who were assigned to treatment and received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"From first dose of study treatment until death or up to approximately 4 years (clinical DCO of 20 Apr 2023)","title":"Dose-Expansion Phase Only: PFS","type":"PRIMARY","unitOfMeasure":"months"}